ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VAL Valirx Plc

3.35
0.05 (1.52%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 1.52% 3.35 3.30 3.40 3.35 3.30 3.30 164,059 15:18:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.28 3.02M
Valirx Plc is listed in the Medical Laboratories sector of the London Stock Exchange with ticker VAL. The last closing price for Valirx was 3.30p. Over the last year, Valirx shares have traded in a share price range of 3.25p to 14.75p.

Valirx currently has 90,174,156 shares in issue. The market capitalisation of Valirx is £3.02 million. Valirx has a price to earnings ratio (PE ratio) of -1.28.

Valirx Share Discussion Threads

Showing 19176 to 19195 of 29350 messages
Chat Pages: Latest  778  777  776  775  774  773  772  771  770  769  768  767  Older
DateSubjectAuthorDiscuss
30/9/2020
09:37
Wouldn't be surprised if we see the recent high of 67p in the short term.
7rademark
30/9/2020
09:32
CHESTY, like you have with SNG!!!!
fission453
30/9/2020
09:29
nico will be rubbing his hands having purchased more yesterday, as I guess he will soon feel like cashing in again, some of those extras that do not require a RNS.
clocktower
30/9/2020
09:22
Mcap 16m. Successful pharmas are mcap multi billion. Do the maths sellers.
7rademark
30/9/2020
09:15
Ther will be a FOMO as this market cap is peanuts and Big Pharma will want a slice of 201!!!!
joeblogg2
30/9/2020
09:09
To late the worms not for turning back now fellas you’ve done your bit now back under your covers for the day.
412069
30/9/2020
09:09
What i like from the q&a released yesterday:"The response rate for VAL201 in this trial is reported as 54.5%.""A number of major cancer drugs have been approved on the back of response rates of around 30%. We are therefore very encouraged that we have good early data for VAL201.""Phase 2 study..... such a trial may also include patients with different cancers where VAL201 might provide a benefit."VAL201 :"We now intend to progress discussions with selected contacts."
jungmana
30/9/2020
09:07
Like you were with hawk chesty.
7rademark
30/9/2020
09:04
Some have been seriously shafted here!
chesty1
30/9/2020
08:34
Guys..you haven't see the botton yet. Need to close on 22p or 13p...then I will call it the bottom
go_baby_go
30/9/2020
08:26
The worms turning and fast at that.
412069
30/9/2020
08:26
Interview with Dr Dilly will be released today . Looking forward to that
jungmana
30/9/2020
08:24
Massive reversal coming today. Extremely oversold.
7rademark
30/9/2020
08:23
Mkt cap of 16M when comparable companies at 60M ++ Do think sellers will be regretting soon as license deals cannot be far off!!!
joeblogg2
30/9/2020
08:21
You've just seen the bottom
notknowing
30/9/2020
08:21
No I bought in low teens!

Will be a quid soon!

fission453
30/9/2020
08:16
13-15p it should settle.
go_baby_go
30/9/2020
08:06
Dump continues. Back to sub 20p today
johnsmith777
30/9/2020
07:59
Ahhhhh the penny drops. Fission bought in on the spike?

Don't worry novice trader....you'll be back there shortly.

notknowing
30/9/2020
07:34
A 4% shareholder ( former director at astrazeneca) bought over 500k shares yesterday;Adam Hargreaveshttps://uk.linkedin.com/in/adam-hargreaves-53372abAdam Hargreaves: "British (FRCPath) and American (DiplACVP) board-certified histopathologist with 18 years experience in pharmaceutical drug discovery and development. Special interests and skills in preclinical and translational small molecule, biologic and RNA-based pharmaceutical efficacy/safety assessment, toxicologic endocrinology and cardiology, oncology, pharmacodynamic modelling, target identification and validation, early-stage compound selection, IMPD/IND documentation and FDA, EMA and PMDA submission/interaction"
jungmana
Chat Pages: Latest  778  777  776  775  774  773  772  771  770  769  768  767  Older

Your Recent History

Delayed Upgrade Clock